Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern

The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting applications to establish the Antiviral Drug Discovery (AViDD) program. AViDD will be comprised of multidisciplinary Centers focused on:

  • The discovery and development of new antiviral drug candidates and lead series with the aim of generating a more robust pipeline of novel antivirals targeting the immediate threat of SARS-CoV-2
  • Providing antiviral drug candidates that might quickly pivot to address future viral outbreaks or pandemics

How to Apply

Funding Opportunity Announcement (FOA), AI-21-050 is open until October 22, 2021. Potential applicants are encouraged to review the FOA for further details.

Contact Information

Michael Schaefer, Ph.D.
Phone: 240-627-3364

Antiviral Program for Pandemics

AViDD is part of NIAID's Antiviral Program for Pandemics (APP) which aims to develop antivirals to combat SARS-CoV-2, build sustainable platforms for drug discovery, and develop a pipeline of antivirals against viruses with pandemic potential.

Pre-Application Informational Webinar

On July 23 and 26, 2021, NIAID held a pre-application informational webinar for prospective applicants. We discussed the overall scope and intent of the funding opportunity and the use of the cooperative agreement (U19) mechanism. 

View a recording of the webinar

Frequently Asked Questions

Frequently asked questions about the funding opportunity announcement are available. Get answers to questions such as what viruses and antivirals are in scope, what phase of research will be funded, who is eligible to apply, and how many awards will be given. 

Content last reviewed on